Evotec SE ADR (EVO)vsUnited Therapeutics Corporation (UTHR)
EVO
Evotec SE ADR
$2.52
+7.69%
HEALTHCARE · Cap: $902.78M
UTHR
United Therapeutics Corporation
$541.60
+1.84%
HEALTHCARE · Cap: $23.74B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 321% more annual revenue ($3.18B vs $756.33M). UTHR leads profitability with a 41.9% profit margin vs -21.0%. EVO appears more attractively valued with a PEG of 1.42. UTHR earns a higher WallStSmart Score of 67/100 (B-).
EVO
Hold38
out of 100
Grade: F
UTHR
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for EVO.
Margin of Safety
+62.9%
Fair Value
$1282.02
Current Price
$541.60
$740.42 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Keeps 42 of every $100 in revenue as profit
Strong operational efficiency at 45.0%
Safe zone — low bankruptcy risk
Earnings expanding 24.5% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -18.0% — below average capital efficiency
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : EVO
The strongest argument for EVO centers on Price/Book. PEG of 1.42 suggests the stock is reasonably priced for its growth.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.9% and operating margin at 45.0%.
Bear Case : EVO
The primary concerns for EVO are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio.
Key Dynamics to Monitor
EVO profiles as a turnaround stock while UTHR is a mature play — different risk/reward profiles.
EVO carries more volatility with a beta of 1.12 — expect wider price swings.
UTHR is growing revenue faster at 7.4% — sustainability is the question.
UTHR generates stronger free cash flow (173M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (67/100 vs 38/100), backed by strong 41.9% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Evotec SE ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Evotec SE is a leading global biotechnology company based in Hamburg, Germany, renowned for its comprehensive drug discovery and development solutions tailored for the pharmaceutical and biotech industries. The firm utilizes a collaborative model, partnering with various stakeholders—ranging from established pharmaceutical companies to innovative academic institutions—to propel the advancement of therapeutic programs across numerous modalities, including small molecules, biologics, and cell therapies. With a robust pipeline of projects and a steadfast focus on enhancing patient outcomes, Evotec is well-positioned to capitalize on emerging opportunities in the biopharmaceutical sector, solidifying its pivotal role in driving healthcare innovation.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?